Skip to main content

UBS Group AG

Position in AKBA — Akebia Therapeutics, Inc.

CIK 1610520 ZURICH, V8

Position in AKBA

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$1,069,563
-$333,605 QoQ
Shares Held
769,471
-11.7% QoQ
Ownership
0.278%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 93% Shared 0% None 7%

Common Shares in AKBA Over Time

Shares Held

Position Value (USD)

Derivatives in AKBA

reported options exposure · as of Mar 31, 2026
CallValue
$0
CallShares
0
PutValue
$8,340
PutShares
6,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

UBS Group AG holds $1,510,992,692 across 81 Drug Manufacturers - Specialty & Generic names. AKBA ranks #42 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in AKBA

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,069,563 769,471
2026-03-31 $8,340 6,000
2025-12-31 $1,403,168 871,534
2025-09-30 $9,954,214 3,646,233
2025-06-30 $2,327,641 639,462
2025-03-31 $1,137,426 592,410
2024-12-31 $667,072 351,091
2024-09-30 $202,833 153,662
2024-06-30 $145,683 142,828
2024-03-31 $181,787 99,338
2023-12-31 $194,716 157,030
2023-09-30 $78,349 68,728
2023-06-30 $65,410 71,488
2023-03-31 $49,264 87,975
2022-12-31 $33,900 58,755
2022-09-30 $41,698 131,961
2022-06-30 $46,119 130,652
2022-03-31 $552,454 769,438
2021-12-31 $1,090,788 482,650
2021-09-30 $1,523,072 528,845
2021-06-30 $524,369 138,356
2021-03-31 $1,111,230 328,281
2020-12-31 $381,491 136,247
2020-09-30 $426,857 170,063
2020-06-30 $1,769,812 130,325
2020-03-31 $1,193,751 157,487